Topic: Eli Lilly and Company

Eli Lilly "very much opposed" to merger: CEO

BEIJING (Reuters) - Drugmaker Eli Lilly , which faces plunging sales due to competition and lapsing patents, will not merge with another peer to ride out any rough times ahead, chief executive John Lechleitr said on Saturday.Speaking on the sidelines of a ...

FDA Approves Lilly's Axiron

Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 ...
Nov. 12--To the casual observer, the pharmaceutical industry these days may appear to be engaged in a mammoth game of Monopoly.. Johnson & Johnson offers $2.3 billion for Crucell NV (September); Pfizer Inc. swallows King Pharmaceuticals Inc. for $3.6 billion (October); Eli ...

Diethylstilbestrol

Diethylstilbestrol ( DES ) is a Ruth L. Ozeki .Synthetic estrogens Teratogens Withdrawn drugs Stilbenoids Phenols Carcinogens IARC Group 1 carcinogens Eli Lilly and Company cs: Diethylstilbestrol fr: Di?thylstilbestrol it: Dietilstilbestrolo mk:
Here are a bunch of stories I may not have time to write about but that I still think everybody else should read. Investors in Myriad Genetics, Illumina, and Life Technologies should all watch the video from Jon Steinberg's blog about how ...
So far in 2010, FDA approvals of new small molecule and biological therapies have paced ahead of those in the same period last year, when 27 new treatments, including two vaccines were authorized, according to Fitch Ratings. More late-stage project delays as ...

Bonuses For GSK Pharma Sales Reps Won’t Be Tied to Sales

When GlaxoSmithKline said that bonuses for its U.S. pharma sales reps will no longer be based on, you know, sales, we needed to know more!. Tying bonuses to "company values" discourages sales reps from pushing unapproved uses of drugs and has become ...
Indianapolis, Indiana based Eli Lilly and Company (NYSE: LLY) announced on Thursday morning that it easily beat consensus Wall Street estimates.. The company's revenue climbed 9% to $5.75 billion, aided by a weaker dollar that strengthened overseas sales in dollar terms.. According ...
" The letter demanded that Lilly stop running the ads and make the risk information more prominent.. Increasingly, the FDA wants drug makers to give equal billing to possible risks of taking drugs, not just rattling them off in the last few ...
Eli Lilly (LLY) is one of the largest of the " Eli Lilly's near-term forecast is strong, as Cymbalta continues to gain approval for new indications, and the company focuses on expanding their overseas sales, where they lag competitors like Pfizer (PFE). ...
Previous